Patent Application
20130259917
The present invention relates to antiseptic solution compositions useful in medical clinical and in public environments for topical and systemic disinfection.
Antiseptics are antimicrobial chemical substances that are applied to living tissue/skin to reduce the possibility of infection, sepsis or putrefaction caused by microorganisms, and disinfectants destroy microorganisms found on nonliving objects.
In the second half of the nineteenth century, inspired by Louis Pasteur's germ theory of disease, the doctors Lister, Semmelweis, Tichenor and others introduced antiseptic treatment and surgical methods into their daily work and initiated a completely new quality of medicine: open wounds, surgery, and infectious diseases no longer led to painful death but were cured through topical antiseptics, and later by internal antibiotics.
Many powerful and fast acting antiseptics have been developed by chemists and applied by doctors and households; some have been abandoned because they produced side effects, others because they were just too inexpensive and not sufficiently profitable to the medical industry; a handful, mainly alcohol based antiseptics, became standards.
From the beginning Pasteur and his followers stipulated that disinfection and antiseptic methods are not 100% effective procedures and have to be verified and classified using the “killing rate” on the specific microorganisms reached and attacked by the disinfecting agent. Today we apply “fast acting” and “persistent” topical antiseptics that all should be “broad spectrum”, i.e. effective against a variety of microorganisms. Fast acting antiseptics are measured by significant reduction in strength determined by cultures obtained a few moments (less than minutes) following application of the antiseptic.
The quality of “persistence” refers to the ability of the antiseptic to continue to kill once it is applied and is due to the retention or binding of the chemical in the stratum corneum of the skin after partial evaporation and after rinsing. It is measured by the time for the micro-flora to be restored to the baseline which existed before the application.
Currently there are several fast acting antiseptics, effective within 20 seconds against transient microorganisms which could cause infections. Most of these antiseptics are based on alcohols, iodine solutions, or chlorides. However all these fast acting antiseptics cannot prevent fast repopulation of the depleted (mainly evaporated) “killing ground” where also all the natural body protection (fatty acids, different salts, regulated pH 5.4-5.5) against invasions has been destroyed.
Persistence, as applied in food industry or exhibited in ancient embalming practices, has remained an elusive goal of medical antiseptic technology. Regulating bodies like the FDA have required persistence since the 1970s for any new antiseptic to be approved, with very little response, actually enhancing the utilization of outdated, nonpersistent, alcohol based disinfectants. Additional regulations for new antiseptics to be tested and evaluated as “medications”, in lengthy and costly clinical trials, led to an end to all small enterprise chemical development and production of innovative disinfectants.
Nature has produced the bill: The surviving microorganisms evolved to develop resistance to short acting threats that allow them to immediately recolonize the tissue cleansed by the short persistence antimicrobials with the next transient flora from the next patient or from the next hand grip.
Best practice now requires doctors and care personnel to wash their hands with antiseptics before and after each patient, X times a day! The campaign “Clean Hands” in German hospitals mounted dispenser bottles for disinfectants on each patient's bed, because the walk to the room's door and back would add up to miles and hours every day. But the doctors and caregivers just cannot do it X times a day without heavy damage to their skin and their health. Compliance therefore remains low and the microorganisms are “taking over”: In Germany every year some 800,000 patients (1 out of 20!) fall seriously ill by in-hospital infections; the number of fatal casualties are kept secret by the hospital companies.
The present invention is therefore directed to novel antiseptics and disinfectants which have been designed “bottom up” based on minerals that act as persistent “aseptics” and prevent microorganism from colonizing nonliving surfaces and skin tissue, while maintaining and eventually enforcing the skin's natural protection flora and mechanisms.
In addition to this persistent preventive action, when heavy contamination and invasion of transient microbes requires a new application of the solution, fast acting alcohols and toxic solutions have been added in small percentage. They act fast on the new microorganisms and then evaporate fast, without damaging the natural protection of skin and persistent antiseptic.
The compounds of the present invention include:
1) As a base, a natural fine mineral, preferably calcium fluoride (CaF2), which exhibits a high killing rate on most microorganisms. This mineral is extremely persistent, sticking to the skin or to surface paints for long periods and releasing its killing fluorine ions only “on demand” when there is moisture and warmth. The mineral is extremely stable, releasing into aqueous solution only 16 mg/l water (=16 ppm) and rebinding immediately when the surface becomes dry again. (CaF2 is mined underground in Germany; in some of these mines underground ponds with water thousands of years old are used as miraculous “fountains of youth” and health baths by the local population.) The CaF2 is used in a fine milled form with particles in the range of 0.25-5.0 microns and preferably 0.5-2.5 microns.
2) When in solution CaF2 also releases calcium ions, basic building blocks for skin, bones, teeth, and other body tissues, enforcing them against any damage and supporting the healing and recovery of cuts, abrasion, and general wounds. This free calcium captures other fluorine ions that could be harmful in too high doses.
3) CaF2 has the same pH 5.4 as normal skin (pH 5.4-5.5). It does not degrade the self-defense mechanisms of the skin, as do soaps.
4) Highly toxic and therefore highly efficient antiseptics are added in very low percentage, initiating and amplifying fast antiseptic action on microorganisms when newly applied as a wash to the tissue: e.g. 0.2-2.0% Eau de Javel (KClO) or 10% ethanol work well. In medical hand wash they act fast, then evaporate and release the skin surface with no damage, with the persistent CaF2 still in place.
5) Well known and accepted drugs are added in low percentage, to stabilize and prevent growth of multi-cellular microorganisms like fungi and mildew that are not attacked by the basic CaF2 ions, thus making the compound really “broad spectrum”: e.g. 0.6% esters of salicylic acids work well as fungicide in this compound.
After medical investigation, treatment, or transport, the caregivers can wash their hands X times a day with a new hand wash of these compounds: new transient microbes are killed fast, recolonization is still prevented by the updated CaF2+layer.
The following tables show some formulations of the present invention with different grade of skin/tissue protection and cure.
Antimicrobial efficacy of the spray has been improved by adding aspirin ester, cinnamic acid, quinic acid, citric acid, and hydrogen peroxide into very low concentration watery solutions, mixing in CaF2 oversaturated with Javel water, all finally stabilized with citric acids.
The different components act differently and the resulting spray shows excellent short time action of >log 7 and long time persistency of >log 3.
Staphylococcus aureus
Pseudomonas aeruginosa
Candida albicans
Aspergillus niger
Permitted toxicity levels for all agents are far above actual application. The product will never have toxic effects in humans, even not in repeated use.
On the skin: NO irritation
Allergization: NO allergizations reported.
The persistent antiseptics of the present invention may be used in a variety of forms. For example, the compounds may be added to paint, varnish, plaster, or gypsum to produce structural surfaces having antiseptic and/or fungicidal properties. They may be produced in conventional gel or cream form providing their antiseptic infection-preventing properties in a manner for easy application to the skin. They may be added to common alginate containing components like calcium alginate to produce medical healing and curing creams for open skin wounds or dry skin. They may be added to aqueous gels to produce hair care compounds which act as protection against dryness, rough surface, and microbes. They may be mixed with water and a small percentage of alcohol for use in an automatic dispenser or nebulizer. They may be mixed with latex solutions for use in outdoor applications such as spraying fruit trees against blight. They may be mixed with drinking water for provision to animals which are otherwise easily infested by microbes, such as European honeybees. They may be applied to rubber and polymer as a filler or sealing agent for use in such products as handgrips and handlebars, elevator handrails, and the like, thereby providing persistent protection against bacterial proliferation.
This application is a continuation of U.S. patent application Ser. No. 12/882,296 filed Sep. 15, 2010, which claims priority of U.S. Provisional Patent Applications Ser. No. 61/242,417 filed Sep. 15, 2009; Ser. No. 61/247,675 filed Oct. 1, 2009; and Ser. No. 61/351,392 filed Jun. 4, 2010, which are incorporated herein by reference.
| Number | Date | Country | |
|---|---|---|---|
| 61242417 | Sep 2009 | US | |
| 61247675 | Oct 2009 | US | |
| 61351392 | Jun 2010 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 12882296 | Sep 2010 | US |
| Child | 13897767 | US |
